Taken together, despite the fact that this is only a case series, the detailed characterization of the impact of BRAF/MEK inhibition on tumor infiltrating lymphocytes allows an improved understanding of the underlying immunological and molecular mechanisms of targeted therapy in melanoma. The gene discussed is MAP2K7; the disease is melanoma.